NCT03006939|Unknown
Fluid Balance During Surgery for Ovarian Cancer
Intraoperative Fluid Balance During Cytoreductive Surgery for Ovarian Cancer
Loading search results
Intraoperative Fluid Balance During Cytoreductive Surgery for Ovarian Cancer
Sponsor study identifier
observational
60
1 country
1
Study Start
December 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Extensive tumour debulking challenges both surgeon and anaesthesiologist but promotes survival in late-stage ovarian cancer patients. Little is known about the intraoperative fluid balance and its impact on morbidity and mortality.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2016
Date type not reportedThis date has not been verified as actual or estimated.
December 14, 2016
Actual (reported)December 30, 2016
Actual (reported)December 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
fluid balance
intraoperative fluid balance is determined by the difference between fluid intake and outtake
at the end of surgery
mechanical ventilation
at the timepoint of extubation
mortality
5 years
Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with ovarian cancer
Dept. of Anaesthesiology and Intensive Care Medicine, University of Bonn
Bonn, 53105, Germany
Blood samples are retained to determine the coagulation status as well as the albumine concentration
Martin Soehle, MD, PhD
University Clinic Bonn
First Submitted
December 14, 2016
First Posted
December 30, 2016
Study Start
December 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2019
Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 30, 2016
Record last verified: 2016-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: